Pulse Biosciences Inc (NASDAQ:PLSE) — Market Cap & Net Worth
Market Cap & Net Worth: Pulse Biosciences Inc (PLSE)
Pulse Biosciences Inc (NASDAQ:PLSE) has a market capitalization of $958.23 Million ($958.23 Million) as of May 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9291 globally and #2465 in its home market, demonstrating a -14.10% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pulse Biosciences Inc's stock price $20.83 by its total outstanding shares 67767578 (67.77 Million). Analyse how efficiently does Pulse Biosciences Inc generate cash to see how efficiently the company converts income to cash.
Pulse Biosciences Inc Market Cap History: 2016 to 2026
Pulse Biosciences Inc's market capitalization history from 2016 to 2026. Data shows growth from $440.49 Million to $1.41 Billion (17.53% CAGR).
Index Memberships
Pulse Biosciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.04% | #256 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #953 of 3165 |
Weight: Pulse Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Pulse Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pulse Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
-92163.91x
Pulse Biosciences Inc's market cap is -92163.91 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $440.49 Million | $68.00K | -$9.52 Million | 6477.78x | N/A |
| 2017 | $1.60 Billion | $247.00K | -$25.57 Million | 6474.96x | N/A |
| 2020 | $1.62 Billion | $114.00K | -$49.74 Million | 14183.64x | N/A |
| 2021 | $1.00 Billion | $1.42 Million | -$63.16 Million | 707.78x | N/A |
| 2022 | $187.72 Million | $700.00K | -$58.95 Million | 268.17x | N/A |
| 2023 | $829.48 Million | $-9.00K | -$42.21 Million | -92163.91x | N/A |
Competitor Companies of PLSE by Market Capitalization
Companies near Pulse Biosciences Inc in the global market cap rankings as of May 3, 2026.
Key companies related to Pulse Biosciences Inc by market ranking:
- Intuitive Surgical Inc (NASDAQ:ISRG): Ranked #136 globally with a market cap of $162.57 Billion USD.
- EssilorLuxottica S. A. (PA:EL): Ranked #250 globally with a market cap of $98.12 Billion USD ( €83.93 Billion EUR).
- ESSILORLUXOTTICA 1/2/O.N. (F:ESLC): Ranked #274 globally with a market cap of $93.24 Billion USD ( €79.76 Billion EUR).
- HOYA CORP. ADR/ 1 O.N. (F:HYB0): Ranked #523 globally with a market cap of $50.37 Billion USD ( €43.09 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #136 | Intuitive Surgical Inc | NASDAQ:ISRG | $162.57 Billion | $457.78 |
| #250 | EssilorLuxottica S. A. | PA:EL | $98.12 Billion | €181.25 |
| #274 | ESSILORLUXOTTICA 1/2/O.N. | F:ESLC | $93.24 Billion | €88.50 |
| #523 | HOYA CORP. ADR/ 1 O.N. | F:HYB0 | $50.37 Billion | €150.00 |
Pulse Biosciences Inc Historical Marketcap From 2016 to 2026
Between 2016 and today, Pulse Biosciences Inc's market cap moved from $440.49 Million to $ 1.41 Billion, with a yearly change of 17.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.41 Billion | +51.71% |
| 2025 | $930.45 Million | -21.14% |
| 2024 | $1.18 Billion | +42.24% |
| 2023 | $829.48 Million | +341.88% |
| 2022 | $187.72 Million | -81.30% |
| 2021 | $1.00 Billion | -37.93% |
| 2020 | $1.62 Billion | +77.93% |
| 2019 | $908.76 Million | +17.02% |
| 2018 | $776.62 Million | -51.44% |
| 2017 | $1.60 Billion | +263.08% |
| 2016 | $440.49 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Pulse Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $958.23 Million USD |
| MoneyControl | $958.23 Million USD |
| MarketWatch | $958.23 Million USD |
| marketcap.company | $958.23 Million USD |
| Reuters | $958.23 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pulse Biosciences Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Ca… Read more